Arcutis Biotherapeutics Inc’s filing revealed that its Officer Watanabe Todd Franklin acquired Company’s shares for reported $0.12 million on Nov 04 ’24. In the deal valued at $8.68 per share,13,871 shares were bought.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Matsuda Masaru bought 5,015 shares, generating $43,551 in total proceeds.
Before that, Burnett Patrick bought 15,441 shares. Arcutis Biotherapeutics Inc shares valued at $134,093 were divested by the Officer at a price of $8.68 per share.
Jefferies initiated its Arcutis Biotherapeutics Inc [ARQT] rating to a Buy in a research note published on August 28, 2024; the price target was $15. A number of analysts have revised their coverage, including Mizuho’s analysts, who increased its forecast for the stock in early January from “a Neutral” to “a Buy”. Mizuho also remained covering ARQT and has decreased its forecast on October 26, 2023 with a “Neutral” recommendation from previously “Buy” rating. Goldman revised its rating on October 13, 2023. It rated ARQT as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ARQT
On Monday, Arcutis Biotherapeutics Inc [NASDAQ:ARQT] saw its stock jump 0.58% to $8.72. Over the last five days, the stock has gained 0.11%. Arcutis Biotherapeutics Inc shares have risen nearly 169.97% since the year began. Nevertheless, the stocks have risen 292.79% over the past one year. While a 52-week high of $13.17 was reached on 04/09/24, a 52-week low of $1.76 was recorded on 01/02/24. SMA at 50 days reached $9.72, while 200 days put it at $9.19.
Levels Of Support And Resistance For ARQT Stock
The 24-hour chart illustrates a support level at 8.39, which if violated will result in even more drops to 8.05. On the upside, there is a resistance level at 8.96. A further resistance level may holdings at 9.19. The Relative Strength Index (RSI) on the 14-day chart is 43.55, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.12, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 61.24%. Stochastics %K at 29.69% indicates the stock is a holding.
How much short interest is there in Arcutis Biotherapeutics Inc?
A steep rise in short interest was recorded in Arcutis Biotherapeutics Inc stocks on 2024-10-15, growing by 3.2 million shares to a total of 28.06 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-13 was 24.86 million shares. There was a rise of 11.41%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 07, 2022 when Needham began covering the stock and recommended ‘”a Buy”‘ rating along with a $46 price target.
